Pycnogenol® supplementation improves the control of irritable bowel syndrome symptoms

Panminerva Med. 2018 Jun;60(2):65-69. doi: 10.23736/S0031-0808.18.03419-5.


Background: The aim of this registry was to evaluate the effects of Pycnogenol® on the main symptoms of irritable bowel syndrome (IBS) in otherwise healthy individuals.

Methods: This study included 77 healthy individuals with symptoms of IBS. The patients were divided into three groups: group 1 was treated with Buscopan (10 mg when needed), group 2 (Antispasmina col forte; 50 mg papaverine hydrochloride+10 mg belladonna extract when needed) and 3 (Pycnogenol® 150 mg/day) for 3 weeks.

Results: The number of painful attacks was comparable in all groups after four weeks. Mild pain on manual abdomen pressure was decreased in all groups, with the improvement in the Pycnogenol® group significantly more pronounced that in both control groups (P<0.05). Perceived abdominal bowel movements/distension were significantly relieved in group 2 (Antispasmina Col Forte) and 3 (Pycnogenol®) (P<0.05) in comparison with Buscopan (group 1).

Conclusions: Pycnogenol® has shown a significant, protective and preventive activity on IBS symptoms, and thus it may represent a potential "soft" approach to IBS.

MeSH terms

  • Abdomen
  • Adult
  • Butylscopolammonium Bromide / therapeutic use
  • Dietary Supplements*
  • Female
  • Flavonoids / therapeutic use*
  • Healthy Volunteers
  • Humans
  • Irritable Bowel Syndrome / drug therapy*
  • Male
  • Middle Aged
  • Oxidative Stress
  • Pain
  • Parasympatholytics / therapeutic use
  • Pilot Projects
  • Plant Extracts
  • Pressure
  • Registries


  • Flavonoids
  • Parasympatholytics
  • Plant Extracts
  • Butylscopolammonium Bromide
  • pycnogenols